Aytu BioPharma

Youtube Subscribe

Open: 1.73 Close: 1.72 Change: -0.01

You're losing the opportunity of using an AI to get informed about Aytu BioPharma Stock.

The game is changing. There is a new strategy to evaluate Aytu BioPharma fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Aytu BioPharma are: Aytu, revenue, end, growth, BioPharma, twelve, month, …

Concept Map

Semantic Network

Stock Summary

Aytu Biopharma, Inc. focuses on developing and commercializing novel therapeutics and consumer healthcare products. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in.

Today's Summary

Aytu BioPharma had revenue of $104.12M in the twelve months ending March 31, 2023, with 12.31% growth year-over-year. In the fiscal year ending June 30, 2022, Aytu Biopharma had annual revenue of. $96.67M with 47.29% growth.

Today's News

Aytu BioPharma had revenue of $104.12M in the twelve months ending March 31, 2023, with 12.31% growth year-over-year. In the fiscal year ending June 30, 2022, Aytu Biopharma had annual revenue of. $96.67M with 47.29% growth.

Stock Profile

"Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado."

Keywords

Are looking for the most relevant information about Aytu BioPharma? Investor spend a lot of time searching for information to make investment decisions in Aytu BioPharma. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Aytu BioPharma are: Aytu, revenue, end, growth, BioPharma, twelve, month, and the most common words in the summary are: state, united, therapeutic, inc, biopharma, anonymous, nasdaq, . One of the sentences in the summary was: $96.67M with 47.29% growth.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #state #united #therapeutic #inc #biopharma #anonymous #nasdaq.

Read more →

Youtube Subscribe

---